Pharma & Biotech

Following breakthrough data from the Copenhagen summit, three major labs are pivoting their oncology pipelines toward one of the deadliest cancers.

The GLP-1 wave is reshaping capital allocation across the pharma landscape.

Offshore production facilities face mounting logistical hurdles.